admin – page 15 – eisai china lnc.-威尼斯人888

tokyo, june 21, 2018 – abbvie gk (headquarters: tokyo, president: james feliciano, “abbvie”) and eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that humira® for subcutaneous injection 20 mg syringe 0.2 ml, a new pediatric formulation of humira ® (generic name: adalimumab [recombinant], “humira”), a fully human anti-tnf-α monoclonal antibody formulation, has been launched today after being listed in the national health insurance reimbursement price list on june 15.

tokyo jun 4, 2018 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada), announced today that results from presentations of new data and analyses of lenvima® (lenvatinib), an orally available kinase inhibitor discovered by eisai, in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy, keytruda® (pembrolizumab), in four different tumor types: unresectable hepatocellular carcinoma (hcc) (abstract #4076), squamous cell carcinoma of the head and neck (scchn) (abstract #6016), advanced renal cell carcinoma (rcc) (abstract #4560), and advanced endometrial carcinoma (ec) (abstract #5596 and abstract #5597). the data are included in presentations at the 54th annual meeting of the american society of clinical oncology (asco) in chicago from june 1-5. lenvima and keytruda are not approved for use in combination in any cancer types today.

on may 29, the china human capital forum 2018 was held in china world hotel beijing, announcing that the human resource team of eisai china won the “best hr teams in greater china” of hroot awards 2018 for their outstanding achievements and contributions in pushing the development and innovation of the corporate, building excellent workplaces and promoting business development. mr. yamada koki, head of pharmaceutical affairs division of eisai china, mr. yu ruilong, director of drug affairs & relationship department of eisai china, and ms. wang li, manager of human resource department of eisai china attended the award ceremony. 

eisai co., ltd. (ceo: haruo naito; headquarters: tokyo, japan) (hereinafter “eisai”), eisai‘s subsidiary for gastrointestinal diseases ea pharma co., ltd. (president & ceo: yuji matsue; headquarters: tokyo, japan) (hereinafter “ea pharma”) and mochida pharmaceutical co., ltd. (president: naoyuki mochida; headquarters: tokyo, japan) (hereinafter “mochida”) today announced that the bile acid transporter inhibitor “goofice® 5mg tablet” (nonproprietary name: elobixibat hydrate; development code: ajg533) (hereinafter “goofice® tablet”) was listed in japan’s national health insurance drug price list as of april 18, 2018, and ea pharma and mochida launched the product onto japan‘s market today.

tokyo march 23, 2018 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada), today announced that the multiple receptor tyrosine kinase inhibitor lenvima® (generic name: lenvatinib mesylate) has been approved in japan for unresectable hepatocellular carcinoma (hcc). this is the first approval worldwide for lenvima for the indication of unresectable hcc and the first new systemic therapy to be approved in japan for the front-line treatment of hcc in approximately 10 years. additionally, this is the first regulatory approval for lenvima under the global strategic collaboration agreement executed in march 2018 between eisai and merck & co., inc., kenilworth n.j., u.s.a. for the co-development and co-commercialization of lenvima.